¼¼°èÀÇ ¼¼Æ÷ ±â¹Ý ºÐ¼® ½ÃÀå º¸°í¼­(2025³â)
Cell Based Assays Global Market Report 2025
»óǰÄÚµå : 1824519
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 250 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,469,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,350,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 12,232,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼Æ÷ ±â¹Ý ºÐ¼® ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ±Þ¼ºÀåÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â CAGR 13.1%¸¦ ³ªÅ¸³» 481¾ï 8,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ¼ºÀåÀº AI¿Í ¸Ó½Å·¯´×ÀÇ ÅëÇÕ, ±ÔÁ¦ »óȲÀÇ º¯È­, °í ÄÁÅÙÃ÷ ½ºÅ©¸®´× ¼ö¿ä, Áúº´ ¸ðµ¨¸µÀÇ Áøº¸, Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ Áַ¿¡ ±âÀÎÇÑ´Ù°í »ý°¢µË´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä µ¿Çâ¿¡´Â °í󸮷® ½ºÅ©¸®´×(HTA), 3d ¼¼Æ÷ ¹è¾ç, Àå±â ¿ÂĨ ±â¼ú, CRISPR/cas9 ±â¼ú, À̹Ì¡ ±â¼úÀÇ Áøº¸°¡ Æ÷ÇԵ˴ϴÙ.

ÇâÈÄ 5³â°£ÀÇ ¼ºÀå·ü 13.1%¶ó°í ÇÏ´Â ¿¹ÃøÀº Àüȸ ¿¹ÃøÀ¸·ÎºÎÅÍ 0.2%ÀÇ ¼ÒÆøÀÇ °¨¼Ò¸¦ ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ÀÌ °¨¼Ò´Â ÁÖ·Î ¹Ì±¹°ú ´Ù¸¥ ±¹°¡ °£ÀÇ °ü¼¼ÀÇ ¿µÇâ ¶§¹®ÀÔ´Ï´Ù. °ü¼¼ À庮Àº À̽º¶ó¿¤°ú ij³ª´Ù¿¡¼­ Á¶´ÞÇÏ´Â 3D ¼¼Æ÷ ¹è¾ç ½Ã½ºÅÛ°ú °íÄÜÅÙÆ® ½ºÅ©¸®´× Ç÷§ÆûÀÇ ºñ¿ëÀ» »ó½Â½ÃÄÑ ÀüÀÓ»ó½ÃÇè ÀÏÁ¤À» ´Ã¸®°í °³¹ß ºñ¿ë¿¡ 50¸¸ ´Þ·¯ ÀÌ»óÀ» ´Ã·Á ¹Ì±¹ÀÇ ÀǾàǰ °³¹ßÀ» ¹æÇØÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶ÇÇÑ »óÈ£°ü¼¼¿Í ¹«¿ªÀÇ ±äÀå°ú ÇѰè Áõ°¡·Î ÀÎÇÑ ¼¼°è°æÁ¦¿Í ¹«¿ª¿¡ ´ëÇÑ ¾Ç¿µÇâÀ¸·Î ÀÎÇØ ±× ¿µÇâÀÌ ´õ¿í ±¤¹üÀ§ÇØÁú °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¿¬±¸¿¡¼­ ¼¼Æ÷ ±â¹Ý ºÐ¼®ÀÇ »ç¿ëÀº Áõ°¡ÇÏ´Â °æÇâÀÌ ÀÖÀ¸¸ç, ÃÖÁ¾ ´Ü°èÀÇ ½ÇÆÐ¸¦ ¿ÏÈ­Çϱâ À§ÇØ ½Å¾à °³¹ß¿¡¼­º¸´Ù ¿¹ÃøÀûÀÎ ¼¼Æ÷ ¸ðµ¨·ÎÀÇ À̵¿ÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÀǾàǰÀ» È¿°úÀûÀ¸·Î »ó½ÃÇÏ°í ºñ¿ëÀÌ ¸¹ÀÌ µå´Â Èı⠴ܰ迡¼­ÀÇ ½ÇÆÐ¸¦ °æ°¨ÇÏ´Â °ÍÀÌ Á¦¾à ¾÷°èÀÇ ±Þ¹«À̸ç, ¼¼Æ÷ ±â¹Ý ºÐ¼® ±â¼ú Çõ½ÅÀÇ Áß¿äÇÑ ÃßÁø·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè¾à(IND)ÀÇ 3»ó ÀÓ»ó½ÃÇè ½ÇÆÐ´Â ±â¾÷¿¡ ¼ö¾ï ´Þ·¯¿¡ À̸£´Â ¸¹Àº À繫Àû ¼Õ½ÇÀ» ÃÊ·¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ½Ã±×¸¶ÀÇ º¸°í¼­¿¡ µû¸£¸é, Á¦¾àȸ»çÀÇ ÅõÀÚÀÌÀÍ·üÀº ÇöÀç Èı⠴ܰèÀÇ ½ÇÆÐÀ²À» °í·ÁÇϸé 5%¸¦ ³ªÅ¸³» ±Þ°¨ÇÒ ¼ö ÀÖÀ¸¸ç, ÀÌ´Â ´ëºÎºÐÀÇ ±â¾÷¿¡ ´ëÇØ ¼ö¿ëÇϱ⠾î·Á¿î ¼öÁØÀÔ´Ï´Ù. ¼¼Æ÷ ±â¹Ý ºÐ¼®¿¡¼­ ³ôÀº ÄÁÅÙÃ÷ ½Ã½ºÅÛ°ú µ¥ÀÌÅÍ ºÐ¼®À» Å©°Ô °­È­ÇÏ¸é °úÇÐÀڵ鿡°Ô ¼¼Æ÷ ¹ÝÀÀ¿¡ ´ëÇÑ ´õ ¸¹Àº Á¤º¸¸¦ ²ø¾î³¾ ¼ö ÀÖÀ¸¸ç, ¾à¹°¿¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» µ½°í ¼¼Æ÷ ±â¹Ý ºÐ¼® ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - °Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

KTH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Cell-based assays are experimental tools designed for studying reactions occurring inside cells, allowing researchers to investigate various mechanisms and processes related to cellular function.

The main products and services associated with cell-based assays include consumables, instruments, services, and software. Consumables are items that are used up or depleted during their usage. Instruments commonly used in cell-based assays encompass microplates, microplate readers, high-throughput screening systems, and liquid handling systems. Various consumables essential for these assays include reagents and media, cells and cell lines, probes, and labels. Cell-based assays employ different technologies, such as automated handling, flow cytometry, label-free detection, high-throughput screening, among others. These assays find applications in drug discovery, basic research, ADME (Absorption, Distribution, Metabolism, and Excretion) studies, predictive toxicology, and other research purposes. End-users of cell-based assays include pharmaceutical and biotechnology companies, academic and government research institutes, contract research organizations (CROs), and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The cell-based assays market research report is one of a series of new reports from The Business Research Company that provides cell-based assays market statistics, including cell-based assays industry global market size, regional shares, competitors with a cell-based assays market share, detailed cell-based assays market segments, market trends, and opportunities, and any further data you may need to thrive in the cell-based assays industry. This cell-based assays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cell based assays market size has grown strongly in recent years. It will grow from $27.07 billion in 2024 to $29.41 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to emergence of HTS techniques, integration of automation, utilization of biomarker detection, adoption of microfluidics, introduction of gene editing tools.

The cell based assays market size is expected to see rapid growth in the next few years. It will grow to $48.18 billion in 2029 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to integration of ai and machine learning, shift in regulatory landscape, demand for high-content screening, advancements in disease modeling, focus on precision medicine. Major trends in the forecast period include high-throughput screening (HTA), 3d cell cultures, organ-on-a-chip technology, CRISPR/cas9 technology, advancements in imaging techniques.

The forecast of 13.1% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. drug development by increasing the cost of 3D cell culture systems and high-content screening platforms sourced from Israel and Canada, thereby extending preclinical timelines and adding $500K+ to development costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The utilization of cell-based arrays in research is on the rise, necessitating a shift towards more predictive cellular models in drug discovery to mitigate last-stage failures. The pharmaceutical industry's imperative to effectively bring drugs to market and mitigate costly late-stage failures is a key driver in the innovation of cell-based assays. Failure in Phase III clinical trials of investigational new drugs (IND) can result in substantial financial losses, reaching several hundred million dollars for the company. Sigma's report indicates that the return on investment for pharmaceutical companies could plummet to 5% given the current rate of late-stage failures, an unacceptable level for most companies. Significant enhancements in high-content systems and data analysis in cell-based assays empower scientists to extract more information about cellular responses, aiding informed decision-making in drug discovery and further fueling the growth of the cell-based array market.

The rise in biologics sales is anticipated to significantly boost the cell-based assays market. Biologics, or biological products, are medicines derived from living organisms, encompassing a wide range of products such as vaccines, blood components, allergenics, somatic cells, gene therapies, tissues, and recombinant therapeutic proteins. Cell-based assays play a crucial role in the biologics sector by evaluating functionality, potency, safety, and bio-similarity. For instance, in May 2022, the European Pharmaceutical Review (EPR), a UK-based non-governmental organization, projected that biologics would greatly exceed sales of innovative small molecules in the next five years, with an estimated $120 billion increase in sales by 2027. This trend reflects a significant shift in the pharmaceutical market toward biologic products. Therefore, the growth in biologics sales is driving the expansion of the cell-based assays market.

Major companies in the cell-based assays market are increasingly launching new platforms leveraging advanced technologies, such as cell-based phenotypic assay platforms, to enhance drug discovery efforts. These platforms evaluate cellular responses to compound treatments by integrating sophisticated imaging and analytical tools, often powered by artificial intelligence. For instance, in June 2024, Sphere Fluidics, a UK-based life sciences R&D company, introduced Cyto-Cellect PLUS. This user-friendly Fluorescence Resonance Energy Transfer (FRET) assay allows researchers to accurately measure IgG productivity with high sensitivity. Building on the original Cyto-Cellect Human IgG¥ê Detection Kit, the enhanced version also detects both IgG ¥ê and ¥ë light chains, expanding its utility. The assay is fully compatible with existing Cyto-Mine(R) functionality, enabling single-cell dispensing into 96-well and 384-well plates. Additionally, it meets relevant regulatory standards by being free of animal origins, facilitating its integration into current cell line development processes. Such innovations reflect the ongoing trend toward developing advanced, user-friendly solutions in the cell-based assays market, supporting the growing demand for effective drug discovery tools.

In May 2022, Cell Carta, a Canada-based provider of precision medicine laboratory services, acquired next-generation immune-MRM assays from Precision Assays for an undisclosed amount. This acquisition aims to strengthen Cell Carta's position in the proteomics vertical and enhance its service offerings in precision medicine laboratory services. Precision Assays, a US-based provider of next-generation targeted proteomics testing solutions, played a significant role in this strategic move.

Major companies operating in the cell based assays market include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, GE HealthCare Technologies Inc., Corning Incorporated, Lonza Group Ltd., Charles River Laboratories International Inc., PerkinElmer Inc., Sigma-Aldrich Corporation, Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam plc, BioVision Inc., Promega Corporation, Cell Signaling Technology Inc., BioTek Instruments Inc., Enzo Life Sciences Inc., BioAgilytix Labs LLC, Cisbio International LLC, ProQinase GmbH, QGel SA, Biotium Inc., Selexis SA, Aurelia Bioscience Ltd., Creative Bioarray, Cell Biolabs Inc., Essen BioScience Ltd., Eurofins Scientific SE, DiscoveRx Corporation

North America was the largest region in the cell-based assays market in 2024. Western Europe was the second largest region in the global cell-based assays market share. The regions covered in the cell based assays market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cell based assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The cell-based assay market consists of sales of reagents, cell lines, microplates, microplates, assay kits, probes, and labels. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cell Based Assays Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cell based assays market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cell based assays ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cell based assays market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Cell Based Assays Market Characteristics

3. Cell Based Assays Market Trends And Strategies

4. Cell Based Assays Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Cell Based Assays Growth Analysis And Strategic Analysis Framework

6. Cell Based Assays Market Segmentation

7. Cell Based Assays Market Regional And Country Analysis

8. Asia-Pacific Cell Based Assays Market

9. China Cell Based Assays Market

10. India Cell Based Assays Market

11. Japan Cell Based Assays Market

12. Australia Cell Based Assays Market

13. Indonesia Cell Based Assays Market

14. South Korea Cell Based Assays Market

15. Western Europe Cell Based Assays Market

16. UK Cell Based Assays Market

17. Germany Cell Based Assays Market

18. France Cell Based Assays Market

19. Italy Cell Based Assays Market

20. Spain Cell Based Assays Market

21. Eastern Europe Cell Based Assays Market

22. Russia Cell Based Assays Market

23. North America Cell Based Assays Market

24. USA Cell Based Assays Market

25. Canada Cell Based Assays Market

26. South America Cell Based Assays Market

27. Brazil Cell Based Assays Market

28. Middle East Cell Based Assays Market

29. Africa Cell Based Assays Market

30. Cell Based Assays Market Competitive Landscape And Company Profiles

31. Cell Based Assays Market Other Major And Innovative Companies

32. Global Cell Based Assays Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cell Based Assays Market

34. Recent Developments In The Cell Based Assays Market

35. Cell Based Assays Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â